Female Issues in Psychiatry

Expert Q&A

Mood and Menopause

Topics: Antidepressants | Citalopram | Depressive Disorder | Effexor | Escitalopram | Female Issues in Psychiatry | Fluoxetine | gabapentin | Gender | Hormone Replacement Therapy | Oral Contraceptives | Prozac | Serotonin Specific Reuptake Inhibitors (SSRIs) | SSRIs | Women’s Issues in Psychiatry

TCPR: When does perimenopausal depression tend to start?Dr. Nonacs: It’s during the transition into menopause that women are most vulnerable to depression. And that transition can actually take quite a while, like 5–7 years. TCPR: How does it present?Dr. Nonacs: Often they’ve had a history of depression, but have done fairly well up to this point

Read More
Clinical Update

Treating Sexual Dysfunction in Women

Topics: Addyi | Alternative treatments | Bupropion | Complimentary treatments | Female hypoactive sexual desire disorder | Female Issues in Psychiatry | natural treatments | Sex Therapy | Vyleesi

With the marketing of two new treatments for female sexual dysfunction, one thing is certain: You can expect to see more patients asking for these medications. What’s less certain is whether they will work. Flibanserin (Addyi) and bremelanotide (Vyleesi), the two FDA-approved treatments, both have small effect sizes (0.3–0.4) on various measures o

Read More
News of Note

FDA Approves a Hormonal Injection for Low Libido in Women

Topics: Addyi | Female hypoactive sexual desire disorder | Female Issues in Psychiatry | Low libido | Sexual Dysfunction | Vyleesi | Women’s Issues in Psychiatry

On June 24, 2019, the FDA approved Vyleesi (bremelanotide injection) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Bremelanotide is an analogue of the α-melanocyte-stimulating hormone, which activates melanocortin in the nervous system. This hormone was originally explored as a sunless tanning agent in the 1980s.

Read More